Amphastar Pharmaceuticals, Inc.AMPHNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +4.58% | +4.73% | -0.76% | -4.38% | +1.60% |
| Gross Profit Growth | -5.96% | -9.87% | -2.34% | -9.12% | -3.23% |
| EBITDA Growth | -24.31% | +0.71% | -15.52% | -15.26% | -39.07% |
| Operating Income Growth | -21.51% | -16.37% | -22.32% | -23.60% | -55.62% |
| Net Income Growth | -17.86% | +4.97% | -41.44% | -18.23% | -57.09% |
| EPS Growth | -17.82% | +4.00% | -41.11% | -15.38% | -54.22% |
| EPS Diluted Growth | -14.29% | +8.82% | -37.04% | -12.33% | -52.56% |
| Weighted Average Shares Growth | -0.16% | +0.98% | -1.18% | -4.00% | -4.42% |
| Weighted Average Shares Diluted Growth | -3.82% | -1.80% | -5.89% | -7.53% | -8.07% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -6.80% | +21.62% | -36.56% | -48.50% | -12.31% |
| Free Cash Flow Growth | -14.72% | +15.19% | -47.57% | -60.32% | +2.31% |
| Receivables Growth | +21.85% | +19.54% | +4.68% | +1.90% | +1.26% |
| Inventory Growth | +18.49% | +45.27% | +60.59% | +56.63% | +42.68% |
| Asset Growth | +0.04% | +4.27% | +3.30% | +8.30% | +7.83% |
| Book Value per Share Growth | +22.47% | +13.41% | +13.08% | +10.62% | +11.67% |
| Debt Growth | -6.35% | +4.31% | +4.05% | +5.63% | +4.27% |
| R&D Expense Growth | +26.48% | -11.15% | +41.19% | +13.75% | +6.06% |
| SG&A Expenses Growth | +24.95% | +7.46% | +11.24% | +8.65% | +114.02% |